**Table 1. Potential molecular targets for MRD**

|  |  |
| --- | --- |
| **Molecular targets** | **Frequency** |
| Fusion genes | **25-30%** |
| *PML-RARA* |  |
| *CBFB-MYH11* |  |
| *RUNX1-RUNX1T1* |  |
| *MLL-fusion partner* |  |
| Mutations | **75%** |
| *NPM1* |  |
| *FLT3* |  |
| *RUNX1* |  |
| *MLL-*PTD |  |
| Overexpression | **80%** |
| *WT1* |  |

*Abbreviation: PML-RARA,* [promyelocytic leukemia gene](https://en.wikipedia.org/wiki/Promyelocytic_leukemia_gene) [retinoic acid receptor-alpha](https://en.wikipedia.org/wiki/Retinoic_acid_receptor-alpha)*; CBFB-MYH11,* core-binding factor subunit beta-myosin heavy chain 11; *RUNX1-RUNX1T1,* runt-related transcription factor 1/runt–related transcription factor 1 translocated to 1; *MLL*, mixed-lineage leukemia; *NPM1*, mutated nucleophosmin1; FLT3, Fms-like tyrosine kinase; *MLL-*PTD, mixed-lineage leukemia partial tandem duplications; WT1, Wilm’s Tumor gene.